BioMarin
Chemicals & Related Products · California, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
770 Lindaro St, San Rafael, California, ...Phone Number
(415) 506-6700Website
www.biomarin.comRevenue
$3.4 BillionStock Symbol
BMRNIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
2
2
1
1
1
About BioMarin
BioMarin Pharmaceutical Inc. is a global biotechnology company headquartered in San Rafael, California, founded in 1997. The company develops and commercializes therapies for rare, genetically defined diseases, with a focus on enzyme replacement and other specialized treatments. Its portfolio includes therapies for mucopolysaccharidosis, phenylketonuria, achondroplasia, severe hemophilia A, and Batten disease, with products marketed under brands including Vimizim, Naglazyme, Kuvan, Palynziq, Brineura, Voxzogo, Aldurazyme, and Roctavian. BioMarin operates manufacturing facilities in the U.S. and Ireland and distributes its products globally.Explore more
BioMarin Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioMarin your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if BioMarin had a recent Job posting/layoffs
Check out if BioMarin is spiking on competitors!
Earning: See what the market has to say on BioMarin recently announced quarterly report
Funding: Get notified immidiatlly once BioMarin has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
BioMarin, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at BioMarin
Product Launch: Get notified when BioMarin launches new products
Check if BioMarin has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined BioMarin as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
BioMarin is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioMarin is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioMarin.
BioMarin financials insights
Gather financial insights about BioMarin, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
1999
Stock Offering
$58.5M
BioMarin Tech Stack
A closer look at the technologies used by BioMarin
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Product Launch
Medical Research, Pharmaceuticals
BioMarin News & Media
BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence
Detailed Phase 3 CANOPY-HCH-3 data in children living with hypochondroplasia also featured in a late-breaking oral presentation at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual Meeting VOXZOGO demonstrated statistically significant improvements across multiple...BioMarin (BMRN) Secured 20% U.S. Royalties on Yuviwel. Is Monetizing a Rival Better than Blocking It?
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has converted a global patent dispute with Ascendis Pharma A/S (NASDAQ:ASND) into a royalty-bearing license for Yuviwel, a once-weekly treatment approved to increase linear growth in children aged 2 years and older with achondroplasia and open epiphyses. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will receive royalties equal to 20% of U.S. Yuviwel net […]BioMarin to Participate in Upcoming Investor Conferences
Wells Fargo 21st Annual Healthcare Conference, September 9 at 3:00 pm EST Cantor Global Healthcare Conference 2026, September 10 at 10:20 am EST Citi's 2026 Biopharma Back to School Conference, September 10 at 1:00 pm EST Morgan Stanley 24th Annual Global Healthcare Conference, September...BioMarin Announces Close of the Alesta Therapeutics Acquisition
Acquisition adds ALE1, a potential first oral therapy for hypophosphatasia to clinical pipeline SAN RAFAEL, Calif., Sept. 1, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Alesta Therapeutics. The...
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioMarin
Sign Up For FreeTo access detailed company insights
BioMarin Pharmaceutical Inc. is a global biotechnology company headquartered in San Rafael, California, founded in 1997. The company develops and commercializes therapies for rare, genetically defined diseases, with a focus on enzyme replacement and other specialized treatments. Its portfolio includes therapies for mucopolysaccharidosis, phenylketo... Read More
